Interview with Ming Fong Chen, Superintendent, National Taiwan University…
Could you start with an overview of the hospital’s capabilities and areas of focus in 2010? NTUH is a 2500 bed medical center and JCI accredited. We are a Centre…
Address:
Tel: 886-2-2655-8133
In view of the need for an inter-agency task to carry out the promotion of the biotechnology and pharmaceutical high-tech industries, in November 1995 the Executive Yuan approved the key points for establishing the Biotechnology and Pharmaceutical Industries Program Office (BPIPO, MOEA). In February 1996 the BPIPO was formerly established to implement and promote the biotechnology industry’s development policy and act as a bridge for communication, coordination and integration among agencies. In December 2001, The Executive Yuan’s One-Stop-Service Office for the Biotechnology Industry was established under the BPIPO, with the office being responsible for the integration and coordination of local organizations involved in the various biotech-related approval and application processes, to build up a sound development environment for the biotech industry. The Director of the Industrial Development Bureau, MOEA acted as convener of the Program Office and formed a committee including the heads of the Executive Yuan’s Department of Health; Environmental Protection Administration; Council for Economic Planning and Development; National Science Council; Council of Agriculture; Science & Technology Advisory Group (STAG); Committee for the Development Fund; Department of Industrial Technology, MOEA; Intellectual Property Office, MOEA; and related government agencies; and representatives, academics, and experts from major research organizations and industry to form an inter-agency promotional organization.
The role of the Program Office is to serve as a window for the exchange of vital information between domestic and foreign industry, and to aggressively promote investment in Taiwan. In so doing, the Program Office hopes to accelerate the upgrading of Taiwan’s biotechnology and pharmaceutical industries and promote Taiwan to become an R&D, manufacturing and operations center for the Asia Pacific region, and furthermore to forge ahead to establish a global operations center.
Could you start with an overview of the hospital’s capabilities and areas of focus in 2010? NTUH is a 2500 bed medical center and JCI accredited. We are a Centre…
How would you describe Morris Enterprise to our readers? Morris Enterprise is a distributor of pharmaceuticals, nutraceuticals and cosmoceuticals. The company has a pharmaceutical division in marketing, a division in…
In 2002, when you established Golden Biotech, what was your vision for the company? There has always been a focus on creating drugs to cure cancer: there are many good…
Traditionally and historically, Lilly is very strong in the Asian region. The company has placed a great deal of emphasis on the region for many years. How does Taiwan fit…
Paul Krugman, who won the 2006 Nobel Prize in economics, said that the Taiwanese health care system is the best in the world. Despite this, you are now drafting a…
Pharma Power Biotec was founded in 2002. What was the vision behind the creation of the company, and what did you want to achieve with the company when it was…
In January 2010, the Taiwan FDA was newly created from four existing agencies. What was the vision behind the creation of this new organisation? What did the government want to…
Minister Wu, please tell our readers a little about your background, and how you came to be in charge of the Overseas Compatriot Affairs Commission (OCAC). I graduated from National…
When you created PharmaEssentia, what was the rationale behind coming back to Taiwan? The foundation for the company was laid in 1997. A group of Taiwanese government officials came to…
Yung Shin has a very long and well-regarded history here in Taiwan. Perhaps we could start by you telling our readers about the recent history of the company and its…
Where is NatureWise most focused today as a company? NatureWise is mainly focused on histone deacetylase (HDAC) inhibitors, especially in the new area of anti-cancer target therapy. These HDAC inhibitor…
Unlike many multinational CROs, PAREXEL decided to base its Asia Pacific operations in Taipei instead of Singapore. To what extent was this decision a result of Taiwan’s business environment and…
See our Cookie Privacy Policy Here
